AU2017226960B2 - Clinical assessment of M-protein response in multiple myeloma - Google Patents

Clinical assessment of M-protein response in multiple myeloma Download PDF

Info

Publication number
AU2017226960B2
AU2017226960B2 AU2017226960A AU2017226960A AU2017226960B2 AU 2017226960 B2 AU2017226960 B2 AU 2017226960B2 AU 2017226960 A AU2017226960 A AU 2017226960A AU 2017226960 A AU2017226960 A AU 2017226960A AU 2017226960 B2 AU2017226960 B2 AU 2017226960B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
ser
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017226960A
Other languages
English (en)
Other versions
AU2017226960A1 (en
Inventor
Stefan HÄRTLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys AG
Original Assignee
Morphosys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys AG filed Critical Morphosys AG
Publication of AU2017226960A1 publication Critical patent/AU2017226960A1/en
Priority to AU2024201503A priority Critical patent/AU2024201503A1/en
Application granted granted Critical
Publication of AU2017226960B2 publication Critical patent/AU2017226960B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/561—Immunoelectrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ecology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Electrochemistry (AREA)
  • Peptides Or Proteins (AREA)
AU2017226960A 2016-03-04 2017-03-03 Clinical assessment of M-protein response in multiple myeloma Active AU2017226960B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201503A AU2024201503A1 (en) 2016-03-04 2024-03-07 Clinical assessment of M-protein response in multiple myeloma

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16158714.2 2016-03-04
EP16158714 2016-03-04
PCT/EP2017/055011 WO2017149122A1 (en) 2016-03-04 2017-03-03 Clinical assessment of m-protein response in multiple myeloma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201503A Division AU2024201503A1 (en) 2016-03-04 2024-03-07 Clinical assessment of M-protein response in multiple myeloma

Publications (2)

Publication Number Publication Date
AU2017226960A1 AU2017226960A1 (en) 2018-08-09
AU2017226960B2 true AU2017226960B2 (en) 2024-03-21

Family

ID=55745535

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017226960A Active AU2017226960B2 (en) 2016-03-04 2017-03-03 Clinical assessment of M-protein response in multiple myeloma
AU2024201503A Pending AU2024201503A1 (en) 2016-03-04 2024-03-07 Clinical assessment of M-protein response in multiple myeloma

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201503A Pending AU2024201503A1 (en) 2016-03-04 2024-03-07 Clinical assessment of M-protein response in multiple myeloma

Country Status (10)

Country Link
US (3) US11618789B2 (enExample)
EP (1) EP3423498A1 (enExample)
JP (4) JP7362250B2 (enExample)
KR (1) KR102427948B1 (enExample)
CN (1) CN108699161B (enExample)
AU (2) AU2017226960B2 (enExample)
CA (1) CA3016098A1 (enExample)
IL (2) IL305540B2 (enExample)
SG (1) SG11201806214RA (enExample)
WO (1) WO2017149122A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209730A1 (en) 2018-04-24 2019-10-31 Helena Laboratories Corporation Removal of interfering factors from serum protein electrophoresis profiles
AU2019338999A1 (en) 2018-09-11 2021-03-18 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD38 antibody, antigen-binding fragment thereof, and pharmaceutical use
SG11202107319PA (en) 2019-03-15 2021-08-30 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
WO2023094696A1 (en) * 2021-11-29 2023-06-01 Morphosys Ag Methods for reducing anti-cd38 mab drug interference in serological assays

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936464B1 (en) * 1992-10-02 2005-08-30 Cancer Research Technology Limited Immune responses to fusion proteins
WO2006099875A1 (en) * 2005-03-23 2006-09-28 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US20080066741A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3912610A (en) * 1974-07-23 1975-10-14 Icl Scient Method for electroquantitative determination of proteins
US4102990A (en) * 1977-12-05 1978-07-25 General Electric Company Electrophoretic assay for antigen-antibody reaction based on particle-particle coupling
US4661586A (en) * 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
US4578350A (en) * 1983-09-23 1986-03-25 Syntex (U.S.A.) Inc. Immunoassays employing protected labels
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
CA2329940A1 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US7348139B1 (en) * 2001-04-13 2008-03-25 The Johns Hopkins University School Of Medicine SOCS-1 gene methylation in cancer
US6902669B2 (en) 2002-09-13 2005-06-07 Fleetguard, Inc. Filter cartridge with floating seal
EP1544215A1 (en) 2003-12-17 2005-06-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Human anti-idiotypic antibody fragments that mimic HER-2/neu
RS54056B1 (sr) 2004-02-06 2015-10-30 Morphosys Ag Anti-cd38 humana antitela i njihove upotrebe
MXPA06008700A (es) * 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
CN105535967B (zh) * 2005-02-15 2022-05-03 杜克大学 抗cd19抗体及其在肿瘤学中的应用
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
ES2653664T3 (es) 2005-10-12 2018-02-08 Morphosys Ag Generación y caracterización de anticuerpos terapéuticos obtenidos mediante HuCal GOLD completamente humanos específicos de CD38 humano
EP2046367A4 (en) * 2006-06-07 2009-11-11 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CA2696210A1 (en) * 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
WO2010002911A2 (en) * 2008-06-30 2010-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods and materials for monitoring myeloma using quantitative mass spetrometry
PL2580243T3 (pl) 2010-06-09 2020-05-18 Genmab A/S Przeciwciała przeciwko ludzkiemu CD38
LT2621531T (lt) 2010-09-27 2017-04-10 Morphosys Ag Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui
AU2011307251A1 (en) 2010-09-30 2013-02-28 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-HER3 antibodies
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP2831237B1 (en) 2012-03-30 2017-11-29 The Board of Regents of the University of Oklahoma High molecular weight heparosan polymers and methods of production and use thereof
LT2900232T (lt) 2012-09-25 2018-02-26 Morphosys Ag Deriniai ir jų panaudojimas
DK3677591T5 (da) 2013-04-29 2024-08-26 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b
SG10201803288RA (en) 2013-10-31 2018-05-30 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
PT3105317T (pt) 2014-02-14 2019-02-27 Cellectis Células para imunoterapia manipuladas para atuar sobre antigénios presentes tanto em células imunitárias como em células patológicas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936464B1 (en) * 1992-10-02 2005-08-30 Cancer Research Technology Limited Immune responses to fusion proteins
WO2006099875A1 (en) * 2005-03-23 2006-09-28 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US20080066741A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yazaki, P. et al., 'Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein', Nuclear Medicine and Biology, (2008-02-08), vol. 35, no. 2, pages 151 - 158, doi:10.1016/j.nucmedbio.2007.10.010. *

Also Published As

Publication number Publication date
US20240392034A1 (en) 2024-11-28
IL305540B1 (en) 2024-05-01
WO2017149122A1 (en) 2017-09-08
EP3423498A1 (en) 2019-01-09
IL305540A (en) 2023-10-01
AU2017226960A1 (en) 2018-08-09
JP7362250B2 (ja) 2023-10-17
CA3016098A1 (en) 2017-09-08
IL260750A (enExample) 2018-09-20
US20230203189A1 (en) 2023-06-29
JP2024169455A (ja) 2024-12-05
SG11201806214RA (en) 2018-08-30
JP7331168B2 (ja) 2023-08-22
JP2019513346A (ja) 2019-05-30
US20190077875A1 (en) 2019-03-14
IL260750B2 (en) 2024-02-01
US11618789B2 (en) 2023-04-04
JP7557023B2 (ja) 2024-09-26
KR20180118151A (ko) 2018-10-30
CN108699161B (zh) 2022-06-03
IL260750B1 (en) 2023-10-01
CN108699161A (zh) 2018-10-23
KR102427948B1 (ko) 2022-08-02
JP2022058881A (ja) 2022-04-12
AU2024201503A1 (en) 2024-03-28
JP2023157927A (ja) 2023-10-26
IL305540B2 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
AU2017228055B2 (en) Antibodies specific to human poliovirus receptor (PVR)
AU2020332969B2 (en) Anti-PD-L1 single domain antibodies
JP6092625B2 (ja) ＣＤ１９ｘＣＤ３二重特異性抗体を投与するための投与計画
AU2016381992B2 (en) Method for promoting efficiency of purification of Fc region-containing polypeptide
AU2022290544A1 (en) A group of b7h3 monoclonal antibodies and medical use thereof
CN109422811A (zh) 抗cd47抗体及其用途
AU2019295279B2 (en) Antibody binding to cell adhesion molecule 3
AU2017226960B2 (en) Clinical assessment of M-protein response in multiple myeloma
AU2017252574B2 (en) ALK7 binding proteins and uses thereof
AU2021301921B2 (en) Bispecific antibody and use thereof
US20230044381A1 (en) Anti-human programmed death-1 monoclonal antibody
AU2016293391B2 (en) Humanized anti-S100A9 antibody and uses thereof
JP2020504075A (ja) 免疫チェックポイント阻害剤ｐｄ−１及びｐｄ−ｌ１に対する抗体治療をモニタリングするためのイムノアッセイ及び操作されたタンパク質
AU2022207557A9 (en) Cd73-binding protein and use thereof
US12055552B2 (en) Method for diagnosis based on circulating extracellular vesicles
CN103936858B (zh) 抗cd20抗原的抗体l5h6及其应用
AU2022248779A1 (en) Stable multispecific molecule and use thereof
AU2022437929A1 (en) Antibody molecule against growth and differentiation factor 15 and use thereof
CN121108340A (zh) RORl的抗体及其制备方法和用途
AU2021362977A9 (en) Anti-trop-2 antibody, antigen-binding fragment thereof or mutant thereof, and medical use thereof
AU2022207252A9 (en) MULTISPECIFIC ANTIBODY BINDING TO ActRIIA, ActRIIB, AND Fn14
CN103897059A (zh) 抗cd20抗原的抗体l5h7及其应用
CN120040596A (zh) 抗独特型抗体及其应用
CN103936856A (zh) 抗cd20抗原的抗体l4h7及其应用
AU2021414160A9 (en) Human lifr antigen binding protein, preparation method therefor, and application thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)